Page of

Hepatocellular cancer and venous thromboembolism: Hepatocellular cancer and venous thromboembolism Expert commentary Paul Kooner Expert commentary Paul Kooner 

Hepatocellular cancer and venous thromboembolism: Hepatocellular cancer and venous thromboembolism Expert commentary Paul Kooner Expert commentary Paul Kooner
Chapter:
Hepatocellular cancer and venous thromboembolism: Expert commentary Paul Kooner
Source:
Challenging Concepts in Oncology
Author(s):

Hannah Taylor

DOI:
10.1093/med/9780199688883.003.0010

In the UK, hepatocellular carcinoma (HCC) is the eighteenth commonest malignancy, and the incidence is increasing. Prognosis in untreated HCC is poor, with a 5-year survival of 3% and a median survival of 1–8 months. Surgical resection or transplantation are generally considered the only curative treatment options; however, at presentation, only 20% of patients qualify for surgery. For patients who do not qualify for surgery, but in whom disease is still confined to the liver, palliative locoregional therapies focus on disease control, with 5-year survival rates of between 35% and 75% in selected patients. For patients with disease that has spread beyond the liver, outcomes are poor. Despite treatment with systemic therapies, median overall survival is in the range of 8–10 months. Using a case study approach, this chapter looks at the diagnosis and treatment of HCC, with an additional focus on venous thromboembolism and pulmonary embolic disease in malignancy.

Sign In

Copyright © 2020. All rights reserved.